m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05501
 [1]
m6A modification HAGLR HAGLR IGF2BP2 : m6A sites Direct Enhancement Non-coding RNA HAGLR Regulated Target  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) READER
 Regulator Info 
m6A Target HOXD antisense growth-associated long non-coding RNA (HAGLR)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator HOXD antisense growth-associated long non-coding RNA (HAGLR) LncRNA View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary IGF2BP2 loss inhibited cell proliferation, migration and invasion, and induced cell apoptosis and cell cycle arrest by down-regulating HOXD antisense growth-associated long non-coding RNA (HAGLR) expression in an m6A-dependent manner in thyroid cancer cells.
Responsed Disease Thyroid Cancer ICD-11: 2D10
 Disease Info 
Cell Process Cell proliferative
Cell migration
Cell invasion
Cell cycle arrest
Cell apoptosis
In-vitro Model
 TPC-1 Thyroid gland papillary carcinoma Homo sapiens CVCL_6298
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
2D10: Thyroid Cancer 12 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Lenvatinib Approved [2]
Synonyms
E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide
    Click to Show/Hide
External Link
CID: 9823820
TTD: D0R0FO
DrugBank: DB09078
 Compound Name Cabozantinib Approved [3]
Synonyms
Cabometyx; Cometriq
    Click to Show/Hide
External Link
CID: 25102847
TTD: D0IQ6P
DrugBank: DB08875
 Compound Name Thyrotropin Alfa Approved [4]
External Link
TTD: D0H4TQ
 Compound Name Selpercatinib Approved [5]
Synonyms
MFOVQWYFURMVKU-IWAAJCSBSA-N; 2222755-14-6; LOXO292; ARRY-192; LOXO 292; EX-A2636
    Click to Show/Hide
External Link
CID: 134823904
TTD: D01KOA
 Compound Name Selumetinib Phase 3 [6]
Synonyms
AZD-6244; ARRY142886; AZD6244; AZD 6244; 6UH91I579U; ARRY 142886; ARRY-142886; AZD6244 (Selumetinib); AZD6244(Selumetinib); CHEBI:90227; CHEMBL1614701; MEK inhibitors; Selumetinib (AZD6244); UNII-6UH91I579U
    Click to Show/Hide
External Link
CID: 10127622
TTD: D0T5DP
DrugBank: DB11689
 Compound Name QGE-031 Phase 2 [7]
External Link
TTD: D0J7CH
 Compound Name GI-6207 Phase 2 [8]
External Link
TTD: D0L7VC
 Compound Name AIC100 Phase 1 [9]
External Link
TTD: DP0NU9
 Compound Name CYTO-403 Phase 1 [10]
External Link
TTD: DB2R5Y
 Compound Name Demogastrin Phase 1 [11]
Synonyms
Technetium-99m-Demogastrin 2; Cholecystokinin-2 receptor/gastrin-R binding radiolabeled minigastrinanalogue (medullary thyroid cancer), Biomedica Life Science; 99mTc-Demogastrin 2; 99mTc-N4-Gly-(D)Glu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2
    Click to Show/Hide
External Link
TTD: D0QJ6L
 Compound Name Recombinant TSH superagonists Investigative [12]
Synonyms
Recombinant TSH superagonists (thyroid cancer); TR-1401; TR-1402; Recombinant TSH superagonists (thyroid cancer), Trophogen; TSH superagonist (thyroid cancer/goiter), Trophogen; Thyroid stimulating hormone superagonist (thyroid cancer/goiter), Trophogen
    Click to Show/Hide
External Link
TTD: D0U2DY
 Compound Name ITRI-305 Investigative [13]
Synonyms
RET tyrosine kinase inhibitors, Industrial Technology Research Institute
    Click to Show/Hide
External Link
TTD: D0N5TB
References
Ref 1 IGF2BP2 knockdown suppresses thyroid cancer progression by reducing the expression of long non-coding RNA HAGLR. Pathol Res Pract. 2021 Sep;225:153550. doi: 10.1016/j.prp.2021.153550. Epub 2021 Jul 13.
Ref 2 FDA Approved Drug Products from FDA Official Website. 2018. Application Number: (ANDA) 208627.
Ref 3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5887).
Ref 4 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020898.
Ref 5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
Ref 6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 7 ClinicalTrials.gov (NCT02336425) Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma. U.S. National Institutes of Health.
Ref 8 ClinicalTrials.gov (NCT01856920) A Phase 2 Study of GI-6207 in Patients With Recurrent Medullary Thyroid Cancer. U.S. National Institutes of Health.
Ref 9 ClinicalTrials.gov (NCT04420754) Study of AIC100 in Relapsed/Refractory Thyroid Cancer. U.S. National Institutes of Health.
Ref 10 Clinical pipeline report, company report or official report of Cytocom
Ref 11 99mTc-Demogastrin 2 for CCK 2-receptor scintigraphy in medullary thyroid carcinoma. J Nucl Med. 2008; 49 (Supplement 1):115P.
Ref 12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 255).
Ref 13 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2185).